Related references
Note: Only part of the references are listed.Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia
Giovanni Del Poeta et al.
CANCER (2008)
A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study
E. Nitta et al.
ANNALS OF ONCOLOGY (2007)
B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny
Jennifer H. Anolik et al.
CLINICAL IMMUNOLOGY (2007)
Rituximab-related viral infections in lymphoma patients
Sercan Aksoy et al.
LEUKEMIA & LYMPHOMA (2007)
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Roswitha Forstpointner et al.
BLOOD (2006)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers et al.
BLOOD (2006)
Treatment of non-Hodgkin's lymphoma: A look over the past decade
Bertrand Coiffier
CLINICAL LYMPHOMA & MYELOMA (2006)
High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication
F. Cabanillas et al.
ANNALS OF ONCOLOGY (2006)
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network
B. S. Kahl et al.
ANNALS OF ONCOLOGY (2006)
Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis
Petra Roll et al.
ARTHRITIS AND RHEUMATISM (2006)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkin's lymphoma patient
Ugur Unluturk et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis
MJ Leandro et al.
ARTHRITIS AND RHEUMATISM (2006)
Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient
S Aksoy et al.
CLINICAL AND LABORATORY HAEMATOLOGY (2006)
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK)
M Ghielmini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
SM Horwitz et al.
BLOOD (2004)
Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy:: 9-year follow-up
MS Czuczman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly X 4 schedule
M Ghielmini et al.
BLOOD (2004)
Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network
JD Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma
JD Hainsworth
SEMINARS IN ONCOLOGY (2003)
Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma
JD Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial
JD Hainsworth
SEMINARS IN ONCOLOGY (2002)
Share Paper
